Cell and Gene Therapy Manufacturing Services Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Cell and Gene Therapy Manufacturing Services Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Cell and gene therapy manufacturing services market size is set to record an 18.9% CAGR during 2024-2032 driven by rapid advancements in biotechnology and the increasing prevalence of genetic disorders and chronic diseases. As innovative therapies for conditions like cancer, genetic disorders, and rare diseases continue to emerge, there is a growing demand for specialized manufacturing services to produce high-quality, customized cell and gene therapies. Pharmaceutical companies, biotech firms, and research institutions are increasingly outsourcing their manufacturing needs to specialized service providers to scale up production and ensure compliance with stringent regulatory standards. For instance, in April 2024, Memel Biotech introduced a comprehensive service for advanced therapy development and manufacturing. The complexity of cell and gene therapies also necessitates sophisticated manufacturing processes, which drives demand for expertise and infrastructure provided by dedicated service providers. The overall industry is divided into type, mode, indication, end user, and region. Based on type, the cell and gene therapy manufacturing services market from the gene therapy segment is expected to generate notable revenue by 2032. This is due to its innovative approach in treating genetic disorders and diseases at a molecular level. As gene therapy progresses with advanced techniques, such as CRISPR and viral vector-based methods, the need for specialized manufacturing services to produce these complex therapies has increased. In terms of end user, the cell and gene therapy manufacturing services market value from the hospitals segment is projected to observe a robust CAGR from 2024 – 2032. This is owing to the increasing adoption of advanced therapies for patient treatment within hospital settings. As hospitals expand their capabilities to offer cutting-edge treatments for complex diseases, they rely on specialized manufacturing services to provide high-quality, customized cell and gene therapies. Asia Pacific cell and gene therapy manufacturing services industry size will grow between 2024 and 2032 driven by the increasing prevalence of genetic and chronic diseases, coupled with significant advancements in biotechnology. The expanding healthcare infrastructure and growing investments in R and D activities are enhancing the capabilities for producing sophisticated cell and gene therapies. The supportive government policies and incentives aimed at fostering innovation and improving healthcare outcomes are also contributing to regional market expansion.